Aigen Investment Management, LP Alnylam Pharmaceuticals, Inc. Transaction History

Aigen Investment Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $3.18 Million - $4.3 Million	-21,717 Reduced 88.48%	2,827 $422,000
Q4 2023 Feb 09, 2024	BUY	$151.41 - $196.57 $3.72 Million - $4.82 Million	24,544 New	24,544 $4.7 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $2.22 Million - $2.54 Million	11,978 Added 81.9%	26,604 $5.05 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $1.42 Million - $1.83 Million	7,767 Added 113.24%	14,626 $2.93 Million
Q4 2022 Feb 10, 2023	BUY	$185.53 - $241.31 $915,776 - $1.19 Million	4,936 Added 256.68%	6,859 $1.63 Million
Q3 2022 Nov 09, 2022	BUY	$138.54 - $232.0 $266,412 - $446,136	1,923 New	1,923 $385,000
Q2 2022 Aug 02, 2022	SELL	$120.42 - $169.29 $411,836 - $578,971	-3,420 Closed	0 $0
Q1 2022 May 05, 2022	BUY	$127.18 - $173.91 $434,955 - $594,772	3,420 New	3,420 $558,000
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $557,289 - $681,977	-3,283 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$128.63 - $176.89 $422,292 - $580,729	3,283 New	3,283 $557,000

645

109M

1.28M

1.22M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $32.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.